Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ProMIS Neurosciences ( (PMN) ) has shared an update.
On January 27, 2025, ProMIS Neurosciences Inc. announced an updated corporate presentation highlighting its focus on addressing unmet needs in neurodegenerative diseases. The company has a diverse pipeline, including the lead program PMN310 for Alzheimer’s, which is undergoing a Phase 1b clinical trial. The company emphasizes its potential to develop safer, more effective therapies by targeting specific misfolded proteins, supported by a seasoned leadership team and significant funding secured in July 2024.
More about ProMIS Neurosciences
ProMIS Neurosciences Inc. operates in the biopharmaceutical industry, focusing on developing therapies for neurodegenerative diseases. The company targets disease-causing misfolded proteins with a pipeline of antibody and vaccine candidates aimed at conditions such as Alzheimer’s, ALS, and Parkinson’s.
YTD Price Performance: -6.98%
Average Trading Volume: 73,812
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $29.22M
For a thorough assessment of PMN stock, go to TipRanks’ Stock Analysis page.
